CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL
Sara Ghorashian,Giovanna Lucchini,Rachel Richardson,Kyvi Nguyen,Craig Terris,Aleks Guvenel,Macarena Oporto-Espuelas,Jenny Yeung,Danielle Pinner,Jan Chu,Lindsey Williams,Ka-Yuk Ko,Chloe Walding,Kelly Watts,Sarah Inglott,Rebecca Thomas,Christopher Connor,Stuart Adams,Emma Gravett,Kimberly Gilmour,Alka Lal,Sangeetha Kunaseelan,Bilyana Popova,Andre Lopes,Yenting Ngai,Allan Hackshaw,Evangelia Kokalaki,Milena Balasch Carulla,Khushnuma Mullanfiroze,Arina Lazareva,Vesna Pavasovic,Anupama Rao,Jack Bartram,Ajay Vora,Robert Chiesa,Juliana Silva,Kanchan Rao,Denise Bonney,Robert Wynn,Martin Pule,Rachael Hough,Persis J Amrolia
DOI: https://doi.org/10.1182/blood.2023020621
IF: 20.3
2024-01-11
Blood
Abstract:CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22 generated by lentiviral cotransduction with vectors encoding our previously described fast-off rate CD19 CAR (AUTO1) combined with a novel CD22 CAR capable of effective signaling at low antigen density. Twelve patients with advanced B-cell acute lymphoblastic leukemia were treated (CARPALL [Immunotherapy with CD19/22 CAR Redirected T Cells for High Risk/Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia] study, NCT02443831), a third of whom had failed prior licensed CAR therapy. Toxicity was similar to that of AUTO1 alone, with no cases of severe cytokine release syndrome. Of 12 patients, 10 (83%) achieved a measurable residual disease (MRD)-negative complete remission at 2 months after infusion. Of 10 responding patients, 5 had emergence of MRD (n = 2) or relapse (n = 3) with CD19- and CD22-expressing disease associated with loss of CAR T-cell persistence. With a median follow-up of 8.7 months, there were no cases of relapse due to antigen-negative escape. Overall survival was 75% (95% confidence interval [CI], 41%-91%) at 6 and 12 months. The 6- and 12-month event-free survival rates were 75% (95% CI, 41%-91%) and 60% (95% CI, 23%-84%), respectively. These data suggest dual targeting with cotransduction may prevent antigen-negative relapse after CAR T-cell therapy.